

Revolution in Oncology: Artificial Intelligence and Precision Medicine

**Presenter : Mohammad Amin Shahram
M.Sc. in Medical Imaging**

✉ aminshahram530@gmail.com

Artificial Intelligence (AI)

➤ Definition

- Simulation of human intelligence using algorithms and systems
- Capable of learning, reasoning, and decision-making

➤ History

- 1950s: Early algorithms and concept introduction
- 1980s-1990s: Neural networks & deep learning emergence
- 2000s onwards: Medical applications

➤ AI in Medicine

- Disease diagnosis
- Treatment prediction and optimization
- Clinical data management



AI in Oncology

➤ Why AI is Crucial in Oncology ?

- **Global Impact** : Cancer is the second leading cause of death worldwide.
- **Clinical Challenges** : Faster diagnoses, effective treatments, cost reductions.

➤ Contributions of AI in Oncology

- **Application in Diagnosis** : Tumor detection in MRI, CT, PET
- **Complex Data Management** : Integrating genetic, clinical, and treatment data
- **Outcome Prediction** : Forecast patient survival
- **Personalized Treatment** : Optimizing treatment plans based on tumor characteristics and therapeutic response



Machine Learning (ML)

➤ **Machine learning is a branch of AI focused on building computer systems that learn from data to identify patterns and make predictions.**

➤ **Stages of Machine Learning in Oncology:**

1.Data Collection:

Gathering large datasets (images, clinical reports, genomic data).

2.Data Preprocessing:

Cleaning, normalizing, and labeling data for better accuracy.

3.Model Training:

Using algorithms (SVM, DT, ANN) to learn from data.

4.Model Testing:

Validating the model with unseen data.

5.Deployment & Monitoring:

Applying the trained model in clinical practice and monitoring its performance.

Types of Machine Learning

1. Supervised Learning


- Definition:** Models learn from labeled data.
- How it works:** Identifies relationships between inputs and outputs to make predictions.
- Examples in Oncology:** Classifying tumors as benign or malignant using MRI data.

2. Unsupervised Learning


- Definition:** Models work with unlabeled data to discover hidden patterns or structures.
- How it works:** Groups similar data points or uncovers correlations.
- Examples in Oncology:** Clustering cancer patients based on genetic profiles.

3. Reinforcement Learning

- Definition:** Models learn through interaction with the environment.
- How it works:** Optimizes decision-making strategies by trial and error.
- Examples in Oncology:** Developing optimal radiotherapy treatment plans.




Types of Machine Learning




Deep Learning (DL)

- **Deep Learning is a subset of ML using layered neural networks to handle complex data.**
- **Key Components of Deep Learning :**
 - **Input Layer:** Receives raw data
 - **Hidden Layers:** Processes data through multiple layers of neurons.
 - **Output Layer:** Provides predictions or classifications.
- **Key Features of Deep Learning :**
 - **Automated Feature Extraction**
 - **Handles Complex Data**
 - **High Prediction Accuracy**



The Evolution of AI



Radiomics

- **Radiomics** is an emerging machine learning method that can extract numerical data reflecting biologically important tissue characteristics from medical imaging information.
- **Quantitative features** describe the intensity, texture and geometrical characteristics attributed to the tumor radiographic data.
- These features have been used to build **predictive models** for diagnosis, prognosis, and therapeutic response.

The Importance of Radiomics

- 1) **Non-invasive** : Provides critical information without the need for biopsy or surgery
- 2) **Comprehensive** : Allows for a deeper understanding of tumor heterogeneity by analyzing vast amounts of data from medical images.
- 3) **Cost-Effectiveness** : Radiomics leverages existing medical imaging data, reducing additional testing costs.
- 4) **Personalized Treatment** : Facilitates the development of personalized treatment plans based on the specific characteristics of a patient's tumor.

Clinical Applications of AI in Oncology

Tumor Grading Classification

Early Cancer Detection



**Radiation Therapy
Planning**

Predicting Survival Outcomes

Predicting Treatment Response

AI in Early Detection of Prostate Cancer

Definition: Early detection of cancer involves identifying malignancies at an initial stage when treatment is more likely to be successful.

Application: In prostate cancer, AI algorithms increase the accuracy and efficiency of early cancer detection by analyzing image data from MRI scans.

Importance: Early detection significantly improves patient outcomes and survival rates.

Findings:

- 1) AUC: 0.96 for cancer vs. benign.
- 2) AUC: 0.85 for high-risk vs. low-risk cases.

AI-Optimized Radiation Therapy Planning in Lung Cancer

Definition: Radiation therapy planning designs optimal radiation doses to target lung tumors while sparing healthy tissues, with AI automating tumor identification and dose optimization.

Application: Tumor Segmentation - Dose Optimization


Importance:

- Ensures precise tumor targeting, improving treatment effectiveness.
- Reduces radiation exposure to healthy lung tissues, minimizing side effects.

Findings:

- 1) AI achieves up to 92% accuracy in segmenting lung tumors from CT scans.
- 2) AI improves radiation dose coverage by up to 85%, minimizing damage to healthy tissues.


Radiomics Features in Glioblastoma Patients



INTRODUCTION

- **Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults and most aggressive tumor.**
- **Brain tumors are graded on a I to IV scale (slow to fast grow).**
- **GBM is a grade IV Tumor that develops from star-shaped glial cells (astrocytes)**
- **Glioblastoma accounts for 20% of all intracranial tumors and 60% of astrocytic tumors.**
- **Most common in older patients (45-55y) and more common in men than women.**

SYMPTOMS



DIAGNOSIS

❖ Neurological exam

- A patient with any neurological symptoms will first be given a physical exam that includes neurologic function tests.




❖ Removing a sample of tissue for testing (Biopsy)

- A biopsy can be done with a needle before surgery to remove tissue of tumor .
- The sample of suspicious tissue is analyzed in a laboratory to determine the types of cells and their level of aggressiveness.

❖ Imaging tests

- MRI and CT scans produce detailed images of the brain (Location & Size,...).

PROGNOSIS

- **Patients have exhibited poor prognosis with a median survival of 12–15 months despite radiation therapy.**
- **Several prognostic factors influence the survival of patients with GBM, including clinical characteristics , molecular characteristics and characteristics of MRI.**
- **Poor prognosis  Due to the spatial and temporal intra-tumor heterogeneity.**
- **Genetic heterogeneity  Reduces the value of invasive biopsy-based genomic analysis
 Provides opportunities for non-invasive medical imaging (MRI)**



ADVANTAGES OF RADIOMICS

1

Automatic extraction of radiomics features and offers abundant data relative to qualitative analyses.


2

Promising approach for assisting in developing individual treatment strategies in oncology.

Progress of Radiomics in GBM

- 1) Predict the overall survival**
- 2) Discrimination between pseudoprogression and progressive disease
in GBM patients**
- 3) Classification of GBM**

Workflow



Clinical Significance of the Study

**Improvement in
Treatment Efficacy**

Chemotherapy

Radiotherapy




Drugs

**Reduced oxygen
consumption**

Radiation Dose

**Therapeutic
Strategy**

CONCLUSION



References

- **Ingrisch M, Schneider MJ, Nörenberg D et al. Radiomic analysis reveals prognostic information in T1-weighted baseline magnetic resonance imaging in patients with glioblastoma. 2017;52(6):360–366.**
- **Kickingeder P, Burth S, Wick A, Gotz M, Eidel O, Schlemmer HP, et al. Radiomic profiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models. Radiology. 2017;280:880–9.**
- **Chaddad, A. *et al.* Radiomics in glioblastoma: current status and challenges facing clinical implementation. Front. Oncol. 9, 188–198 (2019).**
- **Beig N, Bera K, Prasanna P et al. Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma. Clin Cancer Res 2020;26(8):1866–1876.**

- **Park JE, Kim HS, Jo Y, Yoo RE, Choi SH, Nam SJ, et al. Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI. Sci Rep (2020) 10(1):4250.**
- **Xi YB, Guo F, Xu ZL, Li C, Wei W, Tian P. et al. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging. 2018;47:1380–7.**
- **H.-H. Cho and H. Park, “Classification of low-grade and high-grade glioma using multi-modal image radiomics features,” in Proceedings of the Engineering in Medicine and Biology Society (EMBC), 39th Annual International Conference of the IEEE, pp. 3081–3084, IEEE, 2017.**



**Thank you
for your attention!**